We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
ACC.24 - A structured approach to treat hypercholesterolemia with an "inclisiran first" strategy in US patients with ASCVD performs much better than usual care, according to Michael Koren. He hopes that the results of VICTORION-INITIATE are a wake-up call to treat patients more aggressively with lipid-lowering therapies.
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Michael Koren, MD is is a practicing cardiologist and Chief Executive Officer at Jacksonville Center for Clinical Research , Jacksonville, FL, US.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of the VICTORION-INITIATE trial
Release date: 7 april 2024
ACC.24 - A structured approach to treat hypercholesterolemia with an "inclisiran first" strategy in US patients with ASCVD performs much better than usual care, according to Michael Koren. He hopes that the results of VICTORION-INITIATE are a wake-up call to treat patients more aggressively with lipid-lowering therapies.
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Michael Koren, MD is is a practicing cardiologist and Chief Executive Officer at Jacksonville Center for Clinical Research , Jacksonville, FL, US.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of the VICTORION-INITIATE trial
Release date: 7 april 2024
Stay current with the best on medical education
